查看“胃或胃食管结合部癌”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[胃或胃食管结合部癌]]([[GC/GEJC]])</strong>是源自胃粘膜上皮或胃食管交界区域的恶性肿瘤。在2026年的肿瘤学定义中，<strong>[[胃食管结合部癌]]([[GEJC]])</strong>因其独特的解剖部位及分子特征，被视为介于食管癌与胃癌之间的独立病理实体。随着<strong>[[分子亚型]]</strong>研究的深入，治疗策略已从传统的“一刀切”转变为基于<strong>[[HER2]]</strong>、<strong>[[MSI/dMMR]]</strong>、<strong>[[PD-L1]]</strong>及<strong>[[CLDN18.2]]</strong>等标志物的精准靶向与免疫联合模式。多学科团队([[MDT]])指导下的围手术期综合治疗及晚期维持治疗显著延长了患者的整体生存期。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">胃/胃食管结合部癌</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gastric and GEJ Cancer·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">GC/GEJC Anatomy & Subtypes</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">关键基因：[[ERBB2]]•[[CLDN18.2]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[ICD-10]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">C16/C16.0</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[Entrez]]ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2064([[ERBB2]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心标志物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[CEA]]•[[CA19-9]]•[[AFP]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">解剖分型</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[SiewertI/II/III]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">高风险因素</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[幽门螺杆菌]]•[[GERD]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026标准</th>
                    <td style="padding: 12px; color: #1e40af;">免疫联合靶向全覆盖</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">发病机制与分子驱动力</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        2026年的分子病理学研究将[[GC/GEJC]]分为四大亚型（基于[[TCGA]]）：[[EBV]]阳性型、[[MSI]]型、基因组稳定型([[GS]])和染色体不稳定型([[CIN]])。
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>HER2 扩增与信号过载：</strong>
            约15%-20%的[[GC/GEJC]]存在<strong>[[ERBB2]]</strong>扩增，通过激活[[MAPK]]及[[PI3K/Akt]]通路诱导细胞不受控增殖。</li>
        <li style="margin-bottom: 12px;"><strong>Claudin 18.2 暴露：</strong>
            [[CLDN18.2]]作为紧密连接蛋白，在胃癌组织中因粘膜极性破坏而暴露，成为2026年最受关注的<strong>[[ADC]]</strong>及双抗靶点。</li>
        <li style="margin-bottom: 12px;"><strong>免疫逃逸机制：</strong>
            肿瘤通过表达[[PD-L1]]结合T细胞表面的[[PD-1]]，利用“免疫刹车”抑制[[效应T细胞]]活性。2026年研究发现，[[GEJC]]比远端胃癌具有更高的突变负荷([[TMB]])。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床分型与外科决策(Siewert分型)</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">分型类别</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">解剖定位(距齿状线)</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">2026标准手术入路</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[SiewertI]]型</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">齿状线上1cm至5cm</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">按<strong>食管癌</strong>处理（经胸食管大部切除）。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[SiewertII]]型</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">齿状线上1cm至线下2cm</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">经腹或经胸隔路径，需保证[[R0切除]]。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[SiewertIII]]型</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">齿状线下2cm至5cm</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">按<strong>胃癌</strong>处理（全胃或近端胃切除）。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：联合治疗的范式跨越</h2>
    <p style="margin: 15px 0; text-align: justify;">
        针对晚期[[GC/GEJC]]，2026版指南确立了以“免疫骨架+分子特征”为核心的路径：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>一线全覆盖免疫联合：</strong> 无论[[PD-L1]]表达，化疗联合<strong>[[替雷利珠单抗]]</strong>或<strong>[[纳武利尤单抗]]</strong>已成为晚期标准一线。基于[[RATIONALE-305]]研究，[[CPS]]≥5的人群获益显著。</li>
        <li style="margin-bottom: 12px;"><strong>HER2 阳性三联方案：</strong> 推荐采用“[[曲妥珠单抗]]+[[PD-1]]抑制剂+化疗”的三联模式，开启了靶向免疫协同的新时代。</li>
        <li style="margin-bottom: 12px;"><strong>CLDN18.2 突破：</strong> 针对高表达患者，<strong>[[佐妥昔单抗]]([[Zolbetuximab]])</strong>联合化疗显著延长了[[PFS]]，成为2026年精准治疗的新支柱。</li>
        <li style="margin-bottom: 12px;"><strong>MSI-H 型去化疗：</strong> 2026年共识建议，高度微卫星不稳定患者可直接选用双免疫检查点阻断（如[[PD-1]]+[[CTLA-4]]）。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[CLDN18.2]]：</strong> 2026年胃癌领域最具商业潜力的全新靶点。</li>
            <li style="margin-bottom: 8px;"><strong>[[FLOT方案]]：</strong> 局晚期[[GC/GEJC]]围手术期化疗的金标准。</li>
            <li style="margin-bottom: 8px;"><strong>[[CPS评分]]：</strong> 综合阳性评分，评估[[PD-1]]抑制剂获益可能性的核心量尺。</li>
            <li style="margin-bottom: 8px;"><strong>[[Siewert分型]]：</strong> 决定[[GEJC]]外科手术入路的最关键解剖分类。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>NCCN Clinical Practice Guidelines in Oncology (2026 Version).</strong> <em>Gastric Cancer and Esophageal & Esophagogastric Junction Cancers.</em><br>
            <span style="color: #475569;">[权威点评]：2026版指南全面提升了[[CLDN18.2]]及[[HER2]]靶点在围手术期综合治疗中的推荐等级。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>[[JanjigianYY]],et al.(2021/2026Update).</strong> <em>First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,gastro-oesophageal junction,and oesophageal adenocarcinoma (CheckMate 649):A phase 3 trial long-term results.</em> <strong>[[The Lancet]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[学术点评]：该项具有里程碑意义的研究，在2026年的长效分析中确认了[[PD-L1]]阳性患者的显著生存红利。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            胃或胃食管结合部癌 (GC/GEJC) · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[PD-1]]•[[HER2]]•[[CLDN18.2]]•[[VEGFR2]]•[[FGFR2b]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[替雷利珠单抗]]•[[曲妥珠单抗]]•[[雷莫西尤单抗]]•[[阿帕替尼]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">分期工具</td>
                <td style="padding: 10px 15px; color: #334155;">[[超声内镜]]•[[PET-CT]]•[[诊断性腹腔镜]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心试验</td>
                <td style="padding: 10px 15px; color: #334155;">[[CheckMate-649]]•[[RATIONALE-305]]•[[SPOTLIGHT试验]]</td>
            </tr>
        </table>
    </div>

</div>